---
figid: PMC11214299__gr3
figtitle: Exploiting the potential of the ubiquitin-proteasome system in overcoming
  tyrosine kinase inhibitor resistance in chronic myeloid leukemia
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC11214299
filename: gr3.jpg
figlink: /pmc/articles/PMC11214299/figure/fig3/
number: F3
caption: The role of E3 ligase and deubiquitinases (DUBs) in TKI resistance. For the
  E3 ligase, CHIP, LRSAM1, and Casitas B-lineage lymphoma (CBL) can directly target
  the ubiquitination of BCR-ABL and CBL can then affect TKI resistance via PI3K/AKT
  and JAK/STAT signaling pathway. Down-regulated FBXW7 can overcome TKI resistance
  by increasing the MYC protein expression and activating p53. On the contrary, low
  expression of SIAH2 inhibits the MYC expression by up-regulating DYRK2 to overcome
  TKI resistance. SKP2 can be regulated by EMIL, MYC, and PI3K/AKT/CREB axis and affect
  TKI resistance by negative control of p27. Besides, the GCA/TRAF6/ULK1 and LZTR1/RAS/MAPK
  axis can also help to confront TKI resistance. For the DUBs, USP9X, USP7, and USP25
  can directly deubiquitinate BCR-ABL and USP10 can indirectly deubiquitinate BCR-ABL
  via SKP2. BCR-ABL can affect USP47 through RAS/ERK and STAT5 signaling pathways
  and further positively regulate Y-box binding protein 1 (YB-1). Also, BCR-ABL/STAT5/miR-202-5P
  axis can regulate USP16 and the latter can influence TKI resistance via caspase-6.
  Moreover, the miR-146a-5p/USP6/GLS1 axis can help to overcome TKI resistance without
  BCR-ABL involvement. TKI, tyrosine kinase inhibitor; ULK1, unc-51-like autophagy-activating
  kinase 1; GCA, grancalcin; LZTR1, leucine zipper-like transcription regulator 1;
  MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase;
  GLS1, glutaminase 1.
papertitle: Exploiting the potential of the ubiquitin-proteasome system in overcoming
  tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
reftext: Xudong Li, et al. Genes Dis. 2024 Sep;11(5):101150.
year: '2024'
doi: 10.1016/j.gendis.2023.101150
journal_title: Genes & Diseases
journal_nlm_ta: Genes Dis
publisher_name: Chongqing Medical University
keywords: Chronic myeloid leukemia | Deubiquitinases | E3 ligase | PROTAC | TKI resistance
  | Ubiquitin-proteasome system
automl_pathway: 0.9488575
figid_alias: PMC11214299__F3
figtype: Figure
redirect_from: /figures/PMC11214299__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC11214299__gr3.html
  '@type': Dataset
  description: The role of E3 ligase and deubiquitinases (DUBs) in TKI resistance.
    For the E3 ligase, CHIP, LRSAM1, and Casitas B-lineage lymphoma (CBL) can directly
    target the ubiquitination of BCR-ABL and CBL can then affect TKI resistance via
    PI3K/AKT and JAK/STAT signaling pathway. Down-regulated FBXW7 can overcome TKI
    resistance by increasing the MYC protein expression and activating p53. On the
    contrary, low expression of SIAH2 inhibits the MYC expression by up-regulating
    DYRK2 to overcome TKI resistance. SKP2 can be regulated by EMIL, MYC, and PI3K/AKT/CREB
    axis and affect TKI resistance by negative control of p27. Besides, the GCA/TRAF6/ULK1
    and LZTR1/RAS/MAPK axis can also help to confront TKI resistance. For the DUBs,
    USP9X, USP7, and USP25 can directly deubiquitinate BCR-ABL and USP10 can indirectly
    deubiquitinate BCR-ABL via SKP2. BCR-ABL can affect USP47 through RAS/ERK and
    STAT5 signaling pathways and further positively regulate Y-box binding protein
    1 (YB-1). Also, BCR-ABL/STAT5/miR-202-5P axis can regulate USP16 and the latter
    can influence TKI resistance via caspase-6. Moreover, the miR-146a-5p/USP6/GLS1
    axis can help to overcome TKI resistance without BCR-ABL involvement. TKI, tyrosine
    kinase inhibitor; ULK1, unc-51-like autophagy-activating kinase 1; GCA, grancalcin;
    LZTR1, leucine zipper-like transcription regulator 1; MAPK, mitogen-activated
    protein kinase; ERK, extracellular signal-regulated kinase; GLS1, glutaminase
    1.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CBL
  - STUB1
  - SIAH2
  - ABL1
  - GCA
  - LZTR1
  - LRSAM1
  - FBXW7
  - DYRK2
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - TRAF6
  - KRAS
  - HRAS
  - NRAS
  - MYC
  - SKP2
  - UXT
  - CREB1
  - CREB3
  - CREB5
  - CREB3L1
  - CREB3L2
  - CREB3L3
  - CREB3L4
  - CREM
  - ATF1
  - ATF2
  - AKT1
  - AKT2
  - AKT3
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - ULK1
  - TP53
  - TP63
  - TP73
  - IFI27
  - PSMD9
  - ZNRD2
  - DCTN6
  - TMED7
  - H3P23
  - PTEN
  - USP7
  - USP25
  - USP10
  - USP32
  - PML
  - AGRP
  - ARTN
  - USP9X
  - USP6
  - EPHB2
  - GLS
  - USP15
  - USP47
  - CASP6
  - YBX1
  - CBL
  - GCA
  - RAS
  - pimozide
---
